Common side effects and major contraindications of sunitinib

Although Sunitinib is widely used in the treatment of a variety of solid tumors, such as renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST), and pancreatic neuroendocrine tumors (pNET), its side effects are widely distributed and require patients and doctors to pay close attention. As a multi-target tyrosine kinase inhibitor, while inhibiting tumor growth, it may also interfere with normal cell metabolism and angiogenesis, thus causing a series of adverse reactions.

The most common adverse reactions include fatigue, loss of appetite, oral mucositis, diarrhea, nausea, vomiting and hypertension, etc. These mostly occur in the initial few cycles of treatment. Some symptoms may be alleviated as treatment progresses or improved through symptomatic treatment. Of particular note is"hand-foot syndrome", which refers to redness, swelling, tingling and even peeling of the palms and soles, which often affects the patient's quality of life. In addition, sunitinib can also cause common symptoms such as dysgeusia, stomach discomfort, indigestion, and mild anemia.

More serious side effects include bleeding events, thrombocytopenia, electrocardiogramQT interval prolongation, increased risk of heart failure, abnormal liver function, and serious infections, such as respiratory and urinary tract infections, sepsis, etc. In addition, delayed postoperative wound healing is also a focus of clinical attention, so the preoperative and postoperative medication time needs to be carefully arranged. Rare but serious complications such as rhabdomyolysis, myopathy, and acute renal failure have been reported in rare cases.

In terms of contraindications, sunitinib is not suitable for use in patients with severe cardiovascular disease, uncontrolled hypertension, or known allergies. At the same time, concomitant use with strong CYP3A4 inducers or inhibitors (such as rifampicin, itraconazole, etc.) should be avoided, because these drugs will affect the metabolism of sunitinib, resulting in excessive or weakened drug efficacy and increasing the risk of side effects.

For women who are pregnant or planning to become pregnant, sunitinib is also a prohibited drug because of its potential toxicity to the fetus. It is not recommended for breastfeeding women to take this product. A comprehensive health assessment should be carried out before treatment, and regular examinations should be carried out during medication to ensure that risks are minimized and efficacy is maximized.

Reference materials:https://www.sutent.com/